Key Takeaways:
Rocket Pharmaceuticals (RCKT) reported a first-quarter loss of 42 cents per share, wider than analyst estimates, as the company pivots to the commercial launch of its recently approved gene therapy, Kresladi.
The results reflect the company's focus on advancing its pipeline, with management highlighting disciplined spending and a strengthened balance sheet. The recent sale of a Priority Review Voucher for $180 million provides significant non-dilutive capital.
Shares of the biotechnology firm fell in trading Friday following the announcement. The company's cash, cash equivalents, and investments stood at $144.4 million as of March 31, with its cash runway now expected to extend into the second quarter of 2028.
The wider-than-expected loss came even as Rocket trimmed operational spending. Research and development expenses fell 12.2% year-over-year to $31.5 million, while general and administrative costs declined 39.8% to $17.1 million, primarily due to lower legal expenses.
The key development for the company is the recent FDA accelerated approval for Kresladi, its gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I). This approval made Kresladi the first FDA-approved gene therapy for children with this rare genetic disorder.
Following the approval, Rocket received a Rare Pediatric Disease Priority Review Voucher (PRV), which it subsequently agreed to sell for $180 million. The company stated the proceeds will be used to fund its cardiovascular pipeline, including its most advanced candidate, RP-A501 for Danon disease.
The FDA lifted a clinical hold on the pivotal study for RP-A501 last August. Rocket is now treating three more patients at a lower dose and expects to discuss the completion of the Phase II study with the FDA in the second half of 2026.
The earnings miss puts near-term pressure on the stock, but the main driver for valuation is now the successful commercialization of Kresladi and progress in the Danon disease program. Investors will be watching for updates on the RP-A501 trial and initial sales figures for Kresladi in the upcoming quarters.
This article is for informational purposes only and does not constitute investment advice.
